Skip to main content
Evidence Snapshot

Gamma-aminobutyric acid receptor subunit alpha-5

CHEMBL5112 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5112
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gamma-aminobutyric acid receptor subunit alpha-5 as ChEMBL target CHEMBL5112, mapped to UniProt P31644. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gamma-aminobutyric acid receptor subunit alpha-5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5112
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31644
Gamma-aminobutyric acid receptor subunit alpha-5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Gamma-aminobutyric acid receptor subunit alpha-5 matters

As of 2026-09-13

Gamma-aminobutyric acid receptor subunit alpha-5 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-5 (UniProt P31644); the current evidence base includes 7 approved drugs, 622 compounds, and 50 assays, with lead potency reaching pChEMBL 10.0.

Protein context
Gamma-aminobutyric acid receptor subunit alpha-5

Gamma-aminobutyric acid receptor subunit alpha-5 Sequence length is 462 aa.

Review this target as Gamma-aminobutyric acid receptor subunit alpha-5, mapped to UniProt P31644. Sequence length is 462 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P31644 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 622 compounds, and 50 assays for this target. The dominant activity type is KI. CHEMBL3681588 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL3681588 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-5 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31644, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

622
Total Compounds
50
Total Assays
7
Approved Drugs
IC50: 19.0, KI: 481.0, EC50: 17.0, KD: 21.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3681588
 10.0 Ki —
No preferred name
CHEMBL3681586
 9.7 Ki —
No preferred name
CHEMBL3676424
 9.5 Ki —
No preferred name
CHEMBL3676421
 9.5 Ki —
No preferred name
CHEMBL3676425
 9.5 Ki —

Approved Drugs

Structure Compound First Approval
FLUMAZENIL
CHEMBL407
 1991
ALPRAZOLAM
CHEMBL661
 1981
TRIAZOLAM
CHEMBL646
 1978
DIAZEPAM
CHEMBL12
 1963
FLUNITRAZEPAM
CHEMBL13280
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5112